US 11,896,662 B2
Multivalent influenza nanoparticle vaccines
Sarathi Boddapati, Germantown, MD (US); Anushree Herwadkar, Clarksburg, MD (US); Jason Wong, Rockville, MD (US); Yen-Huei Lin, Rockville, MD (US); Gale Smith, Germantown, MD (US); and Jing-Hui Tian, Germantown, MD (US)
Assigned to Novavax, Inc., Gaithersburg, MD (US)
Filed by Novavax, Inc., Gaithersburg, MD (US)
Filed on Nov. 24, 2021, as Appl. No. 17/534,659.
Application 17/534,659 is a division of application No. 16/357,876, filed on Mar. 19, 2019, granted, now 11,278,612.
Claims priority of provisional application 62/787,980, filed on Jan. 3, 2019.
Claims priority of provisional application 62/644,623, filed on Mar. 19, 2018.
Prior Publication US 2022/0080039 A1, Mar. 17, 2022
Int. Cl. A61K 39/12 (2006.01); C12N 5/00 (2006.01); A61K 39/145 (2006.01); A61P 31/16 (2006.01); A61K 9/00 (2006.01); A61K 9/51 (2006.01); A61K 39/00 (2006.01)
CPC A61K 39/145 (2013.01) [A61K 9/0051 (2013.01); A61K 9/51 (2013.01); A61P 31/16 (2018.01); A61K 2039/70 (2013.01)] 12 Claims
 
1. A composition comprising:
(i) a first HaSMaN (Hemagglutinin Saponin Matrix Nanoparticle) comprising:
(a) a first ISCOM matrix particle comprising Fraction A of Quillaja Saponaria Molina and not Fraction C of Quillaja Saponaria Molina, and
(b) a first recombinant influenza hemagglutinin (HA) glycoprotein trimer, wherein the HA glycoprotein tail is associated with the first ISCOM matrix particle and wherein the HA glycoprotein head extends distally from the first ISCOM matrix particle;
(ii) a second HaSMaN comprising:
(a) a second ISCOM matrix particle comprising Fraction C of Quillaja Saponaria Molina and not Fraction A of Quillaja Saponaria Molina, and
(b) a second recombinant influenza HA glycoprotein trimer, wherein the HA glycoprotein tail is associated with the second ISCOM matrix particle and wherein the HA glycoprotein head extends distally from the second ISCOM matrix particle; and
(iii) a pharmaceutically acceptable buffer or carrier;
wherein each of the first and the second HA glycoprotein is from a Type A influenza strain, and
wherein each of the first and the second HA glycoprotein contains a transmembrane domain.